Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

NCT03382795 PHASE2 UNKNOWN

In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy

Details

Lead sponsor	Korea University Guro Hospital
Phase	PHASE2
Status	UNKNOWN
Enrolment	63
Start date	Wed Jan 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• EGFR Positive Non-small Cell Lung Cancer

Interventions

• EGFR

Countries

South Korea